alagebrium has been researched along with everolimus in 1 studies
| Studies (alagebrium) | Trials (alagebrium) | Recent Studies (post-2010) (alagebrium) | Studies (everolimus) | Trials (everolimus) | Recent Studies (post-2010) (everolimus) |
|---|---|---|---|---|---|
| 83 | 10 | 31 | 5,631 | 1,289 | 4,579 |
| Protein | Taxonomy | alagebrium (IC50) | everolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 2 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0022 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atlı, Ö; Burukoğlu, D; Ergun, B; Ilgın, S; Musmul, A; Sırmagül, B | 1 |
1 other study(ies) available for alagebrium and everolimus
| Article | Year |
|---|---|
Matrix metalloproteinases are possible targets in monocrotaline-induced pulmonary hypertension: investigation of anti-remodeling effects of alagebrium and everolimus.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Everolimus; Hypertension, Pulmonary; Male; Matrix Metalloproteinases; Monocrotaline; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Thiazoles; Vasodilator Agents | 2017 |